NCT00001906View on ClinicalTrials.gov

Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 1999

Study Completion Date

May 31, 2001

Conditions
Cutaneous Leishmaniasis
Interventions
BIOLOGICAL

Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH